At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
TXA127 +1 moredrug
Likely dose
TXA127 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19
In Brief
A Phase 2 clinical trial evaluating TXA127 and Placebo for COVID-19. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if administration of angiotensin-(1-7) (TXA127) prevents acute kidney injury and deterioration into multi-organ failure in patients with severe COVID-19. Participants will undergo a 10-day treatment with either placebo or study drug. The drug will be administered intravenously for 3 hours once each day for 10 days consecutively.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsConstant Therapeutics LLC
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartFeb 2021
Primary CompletionJun 2021
TodayJul 2026
First PostedMay 26, 2020
Enrollment StartFeb 10, 2021
Primary CompletionJun 10, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.1 years ago
Interventions
TXA127drug
0.5 mg/kg per day
Placebodrug
0.5 mg/kg per day